Voluntis, a portfolio company of the CapDecisif Management specialized in digital therapeutics in diabetes and oncology, has successfully raised €30,1m while listing on Euronext
Voluntis is a digital therapeutics pioneer that empowers people suffering from chronic conditions to self-manage their treatment every day, thus improving real-world outcomes. The company has built a portfolio of solutions targeting the world’s top two therapy areas: diabetes and cancer, and has settled partnerships with leading players in their respective fields: Sanofi, AstraZeneca, Roche, Google.
Use of proceeds include the scale-up of commercial activities in North America and Europe and the development of the company’s proprietary multi-cancer solution. Today Voluntis employs 120 qualified staff located in Paris and Boston.
This is the 5th IPO of a CapDecisif Management portfolio company.